| PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu] Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP … JP Buteau, AJ Martin, L Emmett, A Iravani, S Sandhu, AM Joshua, ... The Lancet Oncology 23 (11), 1389-1397, 2022 | 107 | 2022 |
| Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET? R Alipour, A Azad, MS Hofman Therapeutic advances in medical oncology 11, 1758835919876828, 2019 | 44 | 2019 |
| PRINCE: Phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC). S Sandhu, AM Joshua, L Emmett, LA Spain, L Horvath, M Crumbaker, ... Journal of Clinical Oncology 40 (16_suppl), 5017-5017, 2022 | 23 | 2022 |
| 68Ga-PSMA uptake in combined hepatocellular cholangiocarcinoma with skeletal metastases R Alipour, S Gupta, S Trethewey Clinical nuclear medicine 42 (10), e452-e453, 2017 | 22 | 2017 |
| PET/CT variants and pitfalls in malignant melanoma N Aide, A Iravani, K Prigent, D Kottler, R Alipour, RJ Hicks Cancer Imaging 22 (1), 3, 2022 | 20 | 2022 |
| 577O PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC) SK Sandhu, AM Joshua, L Emmett, L Spain, LG Horvath, M Crumbaker, ... Annals of Oncology 32, S626-S627, 2021 | 19 | 2021 |
| Overall survival with [177Lu] Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase … MS Hofman, L Emmett, S Sandhu, A Iravani, JP Buteau, AM Joshua, ... The Lancet Oncology 25 (1), 99-107, 2024 | 15 | 2024 |
| LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC). S Sandhu, AM Joshua, L Emmett, M Crumbaker, M Bressel, R Huynh, ... Journal of Clinical Oncology 41 (16_suppl), 5005-5005, 2023 | 15 | 2023 |
| The role of 18F‐Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) in assessment of complex invasive fungal disease and opportunistic co … A Longhitano, R Alipour, A Khot, A Bajel, P Antippa, M Slavin, K Thursky Transplant Infectious Disease 23 (3), e13547, 2021 | 12 | 2021 |
| The relationship between tumour dosimetry, response, and overall survival in patients with unresectable Neuroendocrine Neoplasms (NEN) treated with 177Lu … R Alipour, P Jackson, M Bressel, A Hogg, J Callahan, RJ Hicks, G Kong European Journal of Nuclear Medicine and Molecular Imaging 50 (10), 2997-3010, 2023 | 11 | 2023 |
| Evolution: Phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with … S Sandhu, S Subramaniam, MS Hofman, MR Stockler, AJ Martin, ... Journal of Clinical Oncology 41 (6_suppl), TPS271-TPS271, 2023 | 10 | 2023 |
| VIOLET: A phase I/II trial evaluation of radioligand treatment in men with metastatic castration-resistant prostate cancer with [161Tb]Tb-PSMA-I&T. JP Buteau, LK Kostos, R Alipour, P Jackson, L McIntosh, B Emmerson, ... Journal of Clinical Oncology 41 (6_suppl), TPS281-TPS281, 2023 | 9 | 2023 |
| Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial … N Barry, RJ Francis, MA Ebert, ES Koh, P Rowshanfarzad, GM Hassan, ... European Journal of Nuclear Medicine and Molecular Imaging 50 (13), 3970-3981, 2023 | 8 | 2023 |
| Utility of metabolic heterogeneity factor in differentiating malignant versus benign parotid uptake on 18F FDG PET-CT R Alipour, S Smith, SK Gupta American journal of nuclear medicine and molecular imaging 8 (6), 415, 2018 | 5 | 2018 |
| Time-savings analysis of total tumor burden quantification on 68Ga-PSMA-11 PET/CT with deep learning auto-segmentation of organs for automatic physiological uptake removal in … JP Buteau, R Niman, P Wilson, T Susman, A Nelson, R Alipour, M Hofman Journal of Nuclear Medicine 63 (supplement 2), 2205-2205, 2022 | 3 | 2022 |
| QUAD SHOT radiotherapy and doublet immunotherapy in the management of anal mucosal melanoma: A case series of efficacy and toxicity of a novel treatment approach and a review … MJ Higgins, R Alipour, K Pope, KA Ung, DL Kok, MST Chua Clinical Colorectal Cancer 21 (3), e179-e186, 2022 | 2 | 2022 |
| Long-term control of melanoma adrenal metastasis treated with radiotherapy B McCann, M Higgins, DL Kok, W Hong, R Alipour, MST Chua Melanoma Research 32 (3), 166-172, 2022 | 2 | 2022 |
| Nodal metabolic tumour volume on baseline 18F‐FDG PET/CT and overall survival in stage II and III NSCLC patients undergoing curative‐intent … R Alipour, N Bucknell, M Bressel, S Everitt, M MacManus, S Siva, ... Journal of medical imaging and radiation oncology 65 (6), 748-754, 2021 | 2 | 2021 |
| Hydroxymethylene diphosphonate for imaging transthyretin cardiac amyloidosis JC Lee, R Alipour Journal of Nuclear Cardiology 27, 1040-1040, 2020 | 2 | 2020 |
| Quantitative calibration of Tb-161 SPECT/CT in view of personalised dosimetry assessment studies L McIntosh, P Jackson, B Emmerson, JP Buteau, R Alipour, G Kong, ... EJNMMI physics 11 (1), 18, 2024 | 1 | 2024 |
